Metabolic health is not a number.
It is a continuous story
told in signals physicians rarely see.
The published evidence is unambiguous: poor metabolic health drives the majority of premature death and lost healthspan globally — and most of the clinical signals that predict it accumulate silently between appointments. Weight is a proxy. Body composition, bloodwork trends, and biometrics are the real story. MetAi is built to surface it, continuously, for the physicians who can act on it.
Metabolic health is the upstream variable.
Everything else follows.
We have spent decades treating the downstream consequences of metabolic dysfunction — type 2 diabetes, cardiovascular disease, hypertension, liver disease, sleep apnoea, certain cancers — as separate clinical problems. The published evidence increasingly shows they are expressions of the same upstream failure: a metabolic system that has drifted out of range, undetected, for years before disease is declared.
Obesity is linked to 74.7% of all diseases in the Global Burden of Disease study. It contributes to over 5 million deaths annually. But the number that matters most is not BMI — it is visceral fat accumulation, lean mass trajectory, insulin sensitivity trend, and cardiovascular biomarker drift. These signals are changing every day. The clinical encounter captures a snapshot. What happens between snapshots determines longevity.
The physician-patient relationship that drives real metabolic health — the kind that protects healthspan, preserves muscle, and reduces the risk of the diseases that shorten life — requires continuous shared data. MetAi is the clinical intelligence layer that makes that possible between every appointment.
“Muscle mass and strength predict longevity more reliably than BMI. Older adults with greater muscle mass and grip strength consistently live longer and enjoy better functional independence — making lean tissue preservation a longevity intervention, not a cosmetic one.”
What the metabolic health story is actually made of
Weight is a proxy for three underlying clinical realities that physicians need to see directly — and that change continuously between every appointment. Each domain tells a different chapter of the metabolic health story. Together they define whether a patient's trajectory is heading toward longevity or away from it.
The evidence base
MetAi is built on
MetAi is grounded in peer-reviewed literature across metabolic health, longevity medicine, body composition science, biometric monitoring, and behaviour change. Every signal we track, every alert threshold, and every clinical protocol traces back to a specific published finding.
25–39% of GLP-1 trial weight loss is lean tissue, not fat. Without body composition monitoring, this is entirely invisible. Establishes daily BIA as a clinical necessity — not optional — in physician-supervised metabolic medicine.
~⅔ of semaglutide weight loss regained within 12 months of stopping, alongside full reversal of cardiometabolic improvements. Physician-led monitoring cannot end when the prescription begins.
89.5% of weight loss maintained with continued tirzepatide versus near-complete reversal on placebo. Outcomes are a function of continuity — the scientific foundation for MetAi's ongoing care model.
Continuous biological feedback — not periodic measurement — is the primary mechanism of sustained dietary and activity behaviour change across 31 RCTs. Validates MetAi's always-on monitoring architecture over snapshot-based approaches.
Cumulative exposure to high visceral fat — sustained over years — is independently associated with increased cardiovascular disease and all-cause mortality risk. Visceral fat is a longitudinal longevity metric, not a snapshot — the case for MetRX's daily visceral fat tracking.
Weight regain post-GLP-1 cessation is rapid, consistent, and population-wide — independent of drug, dose, and treatment duration. Confirms the need for structured monitoring protocols through and beyond GLP-1 treatment.
Muscle mass and grip strength predict longevity more reliably than BMI. Sarcopenia correlates with faster progression on biological aging clocks. Lean mass preservation in metabolic treatment is a longevity intervention — not a cosmetic consideration.
Only 20% of overweight individuals successfully sustain ≥10% weight loss — and those who do overwhelmingly succeed within a continuous, individualised physician-led partnership. The evidence base for Metamed's clinical model and MetAi's physician-first design.
From evidence to clinical platform
Every module in MetAi maps directly to a clinical signal gap identified in the published literature. This is not a wellness app retrofitted for clinical use. Each design decision — every signal tracked, every alert threshold, every integration — traces back to a specific finding about what physicians need to see between appointments to manage metabolic health and longevity outcomes.
How continuous data becomes
sustainable metabolic health
The published evidence is clear that episodic care cannot produce durable metabolic outcomes. MetAi creates the continuous physician-patient data loop that the research demands — so the 364 days between appointments become part of the clinical record, not a gap in it. Every step in the loop is grounded in published science.
Metamed Health is an early-stage physician-led clinical operator. We do not yet have a published internal outcomes dataset. Every statistic on this page is sourced directly from peer-reviewed literature — cited with full authorship, journal, and year. We will share our own outcomes data transparently as it matures under our clinical programme.
The research above reflects the evidence base that informed how we designed MetAi — not marketing claims. If you would like to review any of the full papers referenced here, please contact us: science@metai.health
Built on the evidence.
Designed for your practice.
See how MetAi translates the published evidence into a daily clinical workflow — body composition, lab intelligence, biometrics, and evidence-validated notes unified in one physician dashboard.